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Summary
Background: Percutaneous patent foramen ovale (PFO) closure is gaining wide acceptance. Aims
of the study were to analyse clinical practice regarding PFO closure in Italy, to study indications,
devices, results, and the follow-up of large series of patients treated by percutaneous PFO
closure.
Methods and patients: Italian patent foramen ovale survey (IPOS) is a prospective, observa-Survey; tional, multi-centric survey that uses a web-based database. The survey lasted 12 months,Transcranial Doppler;
Echocardiography
(November 2007—October 2008). 50 centres participated. Ongoing follow-up will continue up
to 36 months. 1035 patients (m.a. 46 years, 60% females) were included in the registry. Most
subjects were treated due to a previous history of TIA/ischemic stroke (∼80% of patients). PFO
diagnosis and right-to-left shunt (RLS) were assessed by contrast-enhanced transesophageal
(cTEE) and/or transthoracic echocardiography and/or transcranial doppler. An aneurysm of the
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interatrial septum was associated in 41% of patients. Intraprocedural monitoring was assessed
by using cTEE and ﬂuoroscopy in 70% and intracardiac echocardiography in 30% of subjects.
Procedures were performed under general anesthesia and local anesthesia/conscious sedation in
54% and 46% of patients respectively. The most used device for PFO closure was Amplatzer (∼70%
of cases).
Results: The procedure was successful in all patients. Early complications occurred in 24/1035
patients (2.3%): 12/24 (50%) of them had cardiac arrhythmias, 1 subject had a TIA. Data regarding
both clinical and cardio-neurosonological follow-up were assessed in 444/1035 (43%) subjects.
The rate of neurological events and cardiac and extra-cardiac complications were around 3% and
9% up to the 24-month follow-up respectively. A large permanent residual RLS and no RLS were
observed in less than 1% and in ∼82% of patients at the 1-year follow-up, respectively.
Conclusions: Our data conﬁrm that percutaneous PFO closure is a safe procedure. Early compli-
cations and those during follow-up are mostly related to arrhythmias. Longer follow-up is under
way.
© 2012 Elsevier GmbH.
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described [9]. cTCD was performed according to the stan-
dardized procedure agreed on in the Consensus Conference
of Venice [10]. Brieﬂy, the total MB count consisted of all
Open access uIntroduction
During the last years, percutaneous patent foramen ovale
(PFO) closure has gained wide acceptance with a huge
number of patients successfully undergoing this procedure.
Few large databanks exist with mid-long term follow-up
after PFO closure [1—8]. Moreover, the rate of peri- and
post-procedural clinical complications was differently char-
acterized in many studies all over the world.
The aim of our study was, therefore, to analyse clinical
practice regarding PFO closure in Italy, to study indications,
devices used, results of percutaneous PFO closure and to
evaluate a 36-month follow-up of a large series of patients
treated by percutaneous closure.
Waiting for the ﬁnal results, this paper describes early
results concerning crucial aspects related to PFO closure up
to the 24-month follow-up.
Methods and patients
Study design
IPOS is a prospective, observational, multi-centric survey
that uses a web-based database. An independent neuro-
logical evaluation of all cases included in the registry was
assessed. Doubtful or inconsistent reports regarding a neu-
rological recurrence were ruled out.
Study period
The survey lasted 12 months and the patients were enrolled
between November 2007 and October 2008. Ongoing follow-
up will continue up to 36 months.
Flow-chart
Patients’ screening consisted with demographic character-
istics, current medical treatment, neurological evaluation,
indication for PFO closure and RLS evaluation.
Imaging with cardiomorphological data, different devices
and possible complications were indicated during the proce-
dures.
M
a
f
oIn the post-procedural phase early complications,
ength of hospitalization and treatment at discharge were
escribed.
Follow-ups were within the 6th, 12th, 24th and 36th
onth. Data regarding cardiac imaging, residual RLS,
eurological recurrences and/or cardiac extra-cardiac com-
lications were speciﬁed.
ndications
ost subjects who underwent PFO closure had a previ-
us history of TIA/cryptogenic ischemic stroke (∼80% of
atients). The remaining indications were consistent with
igraine with aura, other events of paradoxical embolism
s myocardial or retinal ischemia, residual PFO after a
revious procedure, platypnea—ortheodoxia syndrome, neu-
osurgical procedures in sitting/semisitting position, diving,
hrombophilic status and asymptomatic patients with neu-
oradiological ischemic lesions.
aseline data and PFO diagnosis
ifty Italian cardiology departments accepted to partici-
ate. Forty of them enrolled at least one patient in the
egistry. 1035 patients (mean age 46 years [range 5—75],
19/1035 [60%] females) were included in the registry.
PFO diagnosis and right-to-left shunt (RLS) were
ssessed by contrast-enhanced transesophageal (cTEE)
nd/or transthoracic echocardiography (cTTE) and/or tran-
cranial Doppler (cTCD).
RLS was assessed in a visual semi-quantitative method by
TEE and cTTE: RLS was diagnosed if at least 1 microbubble
MB) appeared early in the left atrium either spontaneously
r after provocative manoeuvres, thus indicating no shunt if
o MB were revealed up to a severe shunt if >20MB occurred.
cTCD methods regarding RLS diagnosis were previously
nder CC BY-NC-ND license.B detected during a time interval of 20 s or less after the
ppearance of the ﬁrst MB. The proposed classiﬁcation is as
ollows: small (0—10 MB), moderate (>10MB, without shower
r curtain pattern), and large (shower or curtain pattern)
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LS. All our patients who exhibited RLS of 5 or more MB
ere considered to have a positive test result [11].
Aneurysm of the interatrial septum (ASA) was diagnosed
n the presence of atrial septal excursion greater than 10mm
eyond the plane of the interatrial septum in the presence
f a base width greater than 15mm. ASA was associated in
23/1035 (41%) patients.
ardiac monitoring
ntraprocedural monitoring was assessed by using TEE and
uoroscopy in 70% and intracardiac echocardiography in 30%
f subjects. Procedures were performed under general anes-
hesia and local anesthesia/conscious sedation in 58% and
2% of patients, respectively. The most used device for PFO
losure was Amplatzer (∼70% of cases).
esults
he procedure was successful in all patients.
arly complications
hey occurred in 24/1035 (2.3%) patients in the peri-
rocedural phase. 12/24 (50%) subjects experienced cardiac
rrhythmia: 5 patients had transient atrial ﬁbrillation (AF),
ne patient a transient bradycardia, one patient a I◦
trioventricular block, 4 had AF and 1 had a wide QRS tachy-
ardia, before starting the procedure, and needed electrical
ardioversion. 2/24 (8.3%) patients had a femoral arteri-
venous ﬁstula, thus needing vascular surgery. 4/24 (16.6%)
ubjects had respiratory problems after general anesthesia.
ne patient experienced a device embolization, retrieved
ercutaneously. One patient had a transient visual loss and
patients had a vagal reaction, allergy to antibiotics, right
oronary spasm and mild pericardial effusion.
ollow-up
oth clinical and cardio-neurosonological follow-ups were
ssessed in 444/1035 (43%), 243/1035 (23.5%) and in
1/1035 (3%) subjects, at the 6- 12- 24-month follow-
p, respectively. Up to the 12-month follow-up, fourteen
eurological recurrences were observed in 12/444 (2.7%)
atients: 8 TIA and 2 hemorrhagic and 4 ischemic strokes.
0/14 (71.5%) neurological recurrences occurred within
he 6-month follow-up. 41 cardiac and extra-cardiac com-
lications occurred in 40/444 (9%) subjects, up to the
2th month. 34/41 (83%) complications were related to
rrhythmias, 16 of them had AF, one atrial ﬂutter, 10
upraventricular paroxysmal tachycardia and the remain-
ng 7 patients non speciﬁc arrhythmic patterns. 7/41
17%) complications were related to myocardial ischemia,
trial erosion, device malposition, gluteal hematoma, apical
hrombus, pericardial effusion and dyspnoea. Most cardiac
omplications (34/41, 83%) occurred within the 6-month
ollow-up. Neither neurological recurrences nor cardiac-
xtra-cardiac complications were observed at the 24-month
ollow-up.
r
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Data concerning residual RLS were available in 401/444
90.3%) and in 198/243 (81.5%) subjects, at the 6- and 12-
onth follow-up, respectively. A large permanent residual
LS was observed in 1/401 (0.25%) and 1/198 (0.5%) patient
t the 6- and 12-month follow-up, respectively.
cTTE was the most utilized diagnostic technique during
he follow-up (47.1%, 42.4% and 74.2% at the 6- 12- 24-month
ollow-up, respectively); successively, in a lesser extent,
ere the data obtained by cTTE plus cTCD (23.2%, 24.3%
nd 16.1% at the 6- 12- 24-month follow-up, respectively).
iscussion
he aim of our study was to analyse the clinical practice
egarding PFO closure in Italy by a prospective, observa-
ional and multi-centric survey using a web-based database.
The number of the entire population that underwent PFO
losure was, to our knowledge, one of the highest among
imilar studies. Although there was a considerable drop in
umber of patients at the follow-up, the absolute amount
s still worthy of note, mostly at the 6- and 12-month. This
ould be explained by the fact that the study was conducted
y cardiologists whose aims were, ﬁrst, to evaluate the suc-
ess of the procedure and possible early complications and,
econd, to assess neurological recurrence and residual RLS.
Nowadays, the only neurological indication for PFO clo-
ure is a cryptogenic stroke or TIA. In our study ∼20% of
he subjects underwent the procedure with other clinical
ndications. The ‘‘enlargement’’ of indications might be due
o a greater effort in primary prevention. The question at
ssue was, therefore, whether all indications were assessed
y neurologists or by other specialists. A closer collaboration
etween neurologists and cardiologists or other specialists
ho work together in the patient’s management is desirable.
Our study showed an absolute technical procedural
uccess, comparable to previous reports [4,8—11]. The
ccurrence of early complications are mostly related to car-
iac arrhythmias as described in previous reports [12—15].
We observed that a 2.7% of patients had neurological
ecurrences with major complications (i.e. ischemic and
emorrhagic stroke), and up to the 1.3% at the 12-month
ollow-up. It is noteworthy that about 70% of these patients
ad neurological recurrences within the 6-month follow-
p. This would indicate that the medical therapy should
e carefully monitored, mostly during the critical process
f endothelization. Previous reports described similar inci-
ence of recurrent thromboembolic events ranging from 0
o 4% per year [16—21].
Cardiac and extra-cardiac complications were around 9%
p to 12-month follow-up, with 83% of them within the
th month. Major, even transient, complications (i.e. AF,
trial ﬂutter, myocardial ischemia, apical thrombus) were
bserved in 19/40 (47.5%) patients. Our data, in line with
revious studies [13,22, Furlan A. CLOSURE I trial. Presented
t the AHA 2010 meeting], draw attention to these critical
dverse events, mostly related to cardiac arrhythmias, thus
ndicating the need to improve the peri- and postprocedu-
al safety and prevention both with technical advances and
edical therapy.
Finally, given the low rate of large permanent residual
LS at the 6- and 12-month follow-up (<1%), considered
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crucial for increased risk of paradoxical embolism, we would
substantially rule out that the re-occurrence of neurological
events in our patients be correlated with the patent fora-
men ovale, as sole cause. Remarkably, Mono et al. recently
described that concurrent etiologies, apart from PFO, were
observed in more than one third of recurrent ischemic
events in 308 patients with cryptogenic ischemic stroke who
received medical therapy or underwent percutaneous PFO
closure [4].
Conclusions
Our data regard early results from Italian Patent Foramen
Ovale Survey and we need a longer follow-up in order to
assess a comprehensive and conclusive evaluation of all
clinical and technical characteristics correlated with a pop-
ulation who underwent percutaneous PFO closure.
Our study would conﬁrm that percutaneous PFO closure is
a safe procedure, pointing out that early complications and
those during follow-up are not uncommon and are mostly
related to cardiac arrhythmias.
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taly); Francesco Chiarella (Struttura semplice di emodi-
amica e interventistica cardiovascolare. UC Cardiologia O
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livari (Emodinamica — Cardiologia Ospedale Ca’ Fondello,
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